- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
FDC has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) following a recent inspection of its manufacturing facility in Baddi, Himachal Pradesh. The EIR indicated "No Observations" (Zero 483’s), confirming a clean inspection for the company’s ANDA applications for Cefuroxime Proxetil tablets and Cefixime 400 mg tablets. This development is a positive indication for FDC, showcasing compliance with FDA standards and enhancing its credibility in the market. Investors should watch closely, as this approval could pave the way for future product launches and strengthen the company's pharmaceutical portfolio.